KYNMOBI^® KYNNECT: The flexibility to meet your patients’ onboarding needs

Comprehensive support

KYNMOBI^® KYNNECT for KYNMOBI^® (apomorphine HCl) is specifically designed to help providers and patients understand and manage the challenges of accessing therapy every step of the way. KYNMOBI^® KYNNECT is a quick phone call away and can assist with the following services:

Titration Education and Support: This optional program offers supplemental in-person and virtual visits with Clinical Educators (CEs) to educate patients about dose titration and support and monitor them throughout the process. CEs communicate with HCPs, patients, and/or care partners before, during, and after titration
Prescription Triage: KYNMOBI^® KYNNECT can triage a prescription to a retail network pharmacy. This can be initiated through an e-prescription sent from your Electronic Health Record (EHR) to TC Script
Patient Follow-up: KYNMOBI^® KYNNECT can provide patient follow-up to help patients get started with their KYNMOBI prescription or answer any other questions that come up along the way
Reimbursement Services: The accurate completion of reimbursement or coverage-related materials is critical. KYNMOBI^® KYNNECT will complete a benefits investigation for each patient case and will initiate a prior authorization (PA) through CoverMyMeds^®, if needed

KYNMOBI^® KYNNECT enrollment form

Access support with CoverMyMeds

CoverMyMeds, an industry-leading PA support service, offers an efficient and no-cost method for providers to complete PA requests. Please visit covermymeds.com to complete initial and reauthorization requests, and any appeal requests for KYNMOBI.

PA assistance with CoverMyMeds

PA support at your offices:

Automates the PA process to free up more time for patient care
Can be accessed online at covermymeds.com or via many EHR systems
Physicians and staff can proactively access and submit a PA prior to writing the prescription

CoverMyMeds is a registered trademark of CoverMyMeds LLC.

Learn about the KYNMOBI
Savings Program

Contact KYNMOBI^® KYNNECT:
1-844-KYNMOBI

M-F, 8AM-8PM ET

Top

I authorize my health plans, physicians, pharmacies, and other healthcare providers (collectively, my “Providers”) to disclose my personal health information relating to my use of KYNMOBI (apomorphine HCl) sublingual film, including my medical condition, treatment, care management, as well as the information provided on this form (collectively, “Personal Health Information” or “PHI”), to Sunovion Pharmaceuticals Inc. and its representatives, agents, and contractors that act on behalf of Sunovion (collectively, “Sunovion”) so that Sunovion may use the information to enroll me in (including verifying my eligibility, as applicable), facilitate my participation in, and administer KYNMOBI^® KYNNECT and any other applicable KYNMOBI patient support programs that may be implemented by Sunovion (collectively, “KYNMOBI Patient Support”). As part of this, Sunovion may use and disclose my Personal Health Information to:

Provide all KYNMOBI Patient Support for which I am eligible and have not opted out of and, where applicable, as prescribed by my doctor or other healthcare provider;
Communicate with my Providers and other third parties as needed to facilitate the provision of KYNMOBI Patient Support;
Contact me and my designated representative(s) regarding this form and my enrollment and participation in KYNMOBI Patient Support, and provide me with related patient support communications, including by mail, email, fax, telephone call, voicemail, text message (including calls and text messages made with an automatic telephone-dialing system or a prerecorded voice) (up to 5 messages per week) (standard message and data rates may apply; you may opt out at any time by replying “STOP”) and through messages left for me that disclose that I take or may take KYNMOBI;
Provide me with educational information about KYNMOBI, in person, online, or by telephone, including information and training regarding my use of KYNMOBI;
Monitor and evaluate KYNMOBI Patient Support for effectiveness, future program development, and other administrative purposes; and
Monitor and report safety information about KYNMOBI, including in communications with the US Food and Drug Administration and other government authorities.

I understand that once my Personal Health Information is disclosed to Sunovion under this authorization, it is no longer protected by federal privacy laws and may be further disclosed by Sunovion. I understand that I may refuse to sign this authorization and my healthcare provider(s) and health plan(s) will not condition my treatment or benefits on whether I sign this Patient Authorization. I understand, however, that if I do not sign this authorization, I may not be able to receive support through KYNMOBI^® KYNNECT. I understand that I am entitled to a copy of this authorization. I understand that I may cancel this authorization at any time by mailing a letter requesting such cancellation to Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA 01752, but that this cancellation will not apply to any information already used or disclosed pursuant to this authorization before the notice of the cancellation is received by Sunovion. This authorization expires ten (10) years from the date of execution or upon such an earlier date as may be mandated by state law, if applicable.